Supplemental material
Open access
5,096
Views
25
CrossRef citations to date
0
Altmetric
Research Article
Investigation of PDE5/PDE6 and PDE5/PDE11 selective potent tadalafil-like PDE5 inhibitors using combination of molecular modeling approaches, molecular fingerprint-based virtual screening protocols and structure-based pharmacophore development
Gülru KayıkDepartment of Chemistry, Istanbul Technical University, Istanbul, Turkey; ;Department of Pharmacy, University of Pisa, Pisa, Italy;
, Nurcan Ş. TüzünDepartment of Chemistry, Istanbul Technical University, Istanbul, Turkey;
& Serdar DurdagiDepartment of Biophysics, School of Medicine, Bahcesehir University, Istanbul, TurkeyCorrespondence[email protected]
Pages 311-330
|
Received 14 Aug 2016, Accepted 04 Oct 2016, Published online: 02 Feb 2017
Related Research Data
Selectivity of avanafil, a PDE5 inhibitor for the treatment of erectile dysfunction: implications for clinical safety and improved tolerability.
Source:
Elsevier BV
hERG potassium channels and cardiac arrhythmia
Source:
Springer Science and Business Media LLC
Pharmacophore based virtual screening, molecular docking and biological evaluation to identify novel PDE5 inhibitors with vasodilatory activity.
Source:
Elsevier BV
Synthesis and SAR of tetracyclic pyrroloquinolones as phosphodiesterase 5 inhibitors
Source:
Elsevier BV
ZINC: A Free Tool to Discover Chemistry for Biology
Source:
American Chemical Society (ACS)
Structural basis of phosphodiesterase 6 inhibition by the C‐terminal region of the γ‐subunit
Source:
Wiley
An insight into the pharmacophores of phosphodiesterase-5 inhibitors from synthetic and crystal structural studies
Source:
Elsevier BV
Why do we need so many chemical similarity search methods
Source:
Elsevier BV
1,7- and 2,7-naphthyridine derivatives as potent and highly specific PDE5 inhibitors
Source:
Elsevier BV
Identification, synthesis and SAR of amino substituted pyrido[3,2b]pyrazinones as potent and selective PDE5 inhibitors.
Source:
Elsevier BV
Combined Receptor and Ligand-Based Approach to the Universal Pharmacophore Model Development for Studies of Drug Blockade to the hERG1 Pore Domain
Source:
American Chemical Society (ACS)
hERG, drugs, and LQTS
Source:
Wiley
NS1643 Interacts around L529 of hERG to Alter Voltage Sensor Movement on the Path to Activation
Source:
Elsevier BV
PRODRG: a tool for high-throughput crystallography of protein–ligand complexes
Source:
International Union of Crystallography (IUCr)
Identification of amino acid residues responsible for the selectivity of tadalafil binding to two closely related phosphodiesterases, PDE5 and PDE6.
Source:
American Society for Biochemistry & Molecular Biology (ASBMB)
Computational Analysis of the Mechanism and Thermodynamics of Inhibition of Phosphodiesterase 5A by Synthetic Ligands.
Source:
American Chemical Society (ACS)
In silico prediction of novel phosphodiesterase type-5 inhibitors derived from Sildenafil, Vardenafil and Tadalafil.
Source:
Elsevier BV
Phosphodiesterase 11: a brief review of structure, expression and function
Source:
Springer Science and Business Media LLC
The discovery of tadalafil: a novel and highly selective PDE5 inhibitor. 2: 2,3,6,7,12,12a-hexahydropyrazino[1',2':1,6]pyrido[3,4-b]indole-1,4-dione analogues.
Source:
American Chemical Society (ACS)
hERG1 Pore and Voltage-Sensing Domains
Source:
Wiley
Novel, potent, and selective phosphodiesterase 5 inhibitors : Synthesis and biological activities of a series of 4-aryl-1-isoquinolinone derivatives
Source:
American Chemical Society (ACS)
Design, Synthesis and Biological Activity of β-Carboline-Based Type-5 Phosphodiesterase Inhibitors.
Source:
Wiley
Multiple Conformations of Phosphodiesterase-5: Implications for enzyme function and drug development
Source:
American Society for Biochemistry & Molecular Biology (ASBMB)
Furoyl and benzofuroyl pyrroloquinolones as potent and selective PDE5 inhibitors for treatment of erectile dysfunction.
Source:
American Chemical Society (ACS)
Expression of the PDE5 enzyme on human retinal tissue: new aspects of PDE5 inhibitors ocular side effects
Source:
Springer Science and Business Media LLC
Determinants for Phosphodiesterase 6 Inhibition by Its γ-Subunit
Source:
American Chemical Society (ACS)
In Silico Mapping of Essential Residues in the Catalytic Domain of PDE5 Responsible for Stabilization of Its Commercial Inhibitors
Source:
Multidisciplinary Digital Publishing Institute
A conformational switch in the inhibitory gamma-subunit of PDE6 upon enzyme activation by transducin.
Source:
American Chemical Society (ACS)
Highly potent and selective chiral inhibitors of PDE5: An illustration of Pfeiffer’s rule
Source:
Elsevier BV
Combining 2D and 3D in silico methods for rapid selection of potential PDE5 inhibitors from multimillion compounds' repositories: Biological evaluation
Source:
Springer Science and Business Media LLC
The discovery of novel, potent and selective PDE5 inhibitors.
Source:
Elsevier BV
Development and validation of a genetic algorithm for flexible docking.
Source:
Elsevier BV
Structural determinants of phosphodiesterase 6 response on binding catalytic site inhibitors.
Source:
Elsevier BV
Modeling of open, closed, and open-inactivated states of the hERG1 channel: structural mechanisms of the state-dependent drug binding.
Source:
American Chemical Society (ACS)
The Molecular Basis for the Selectivity of Tadalafil toward Phosphodiesterase 5 and 6: A Modeling Study
Source:
American Chemical Society (ACS)
Efficacy and selectivity of phosphodiesterase-targeted drugs in inhibiting photoreceptor phosphodiesterase (PDE6) in retinal photoreceptors
Source:
Association for Research in Vision and Ophthalmology (ARVO)
Structure of the catalytic domain of human phosphodiesterase 5 with bound drug molecules
Source:
Springer Science and Business Media LLC
Synthesis and phosphodiesterase 5 inhibitory activity of novel pyrido[1,2-e]purin-4(3H)-one derivatives.
Source:
Elsevier BV
Insights into the molecular mechanism of hERG1 channel activation and blockade by drugs.
Source:
Bentham Science Publishers Ltd.
8-(3-chloro-4-methoxybenzyl)-8H-pyrido[2,3-d]pyrimidin-7-one derivatives as potent and selective phosphodiesterase 5 inhibitors.
Source:
Elsevier BV
Phosphodiesterase 5 inhibitors: current status and potential applications
Source:
Springer Science and Business Media LLC
Phosphodiesterase inhibitors and the eye.
Source:
Wiley
Sildenafil (VIAGRATM), a potent and selective inhibitor of type 5 cGMP phosphodiesterase with utility for the treatment of male erectile dysfunction
Source:
Elsevier BV
Related research
People also read lists articles that other readers of this article have read.
Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.
Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.